Using KG1a, an AML cell line that is resistant to NK cell lysis and chemotherapy [24], and CD34+ primary AML samples, which are resistant to apoptosis [31], the data presented further supports the effectiveness of DNTs against therapy-resistant cells. Here, CD34 is linked to acute myeloid leukemia.